Speaker Survey

Dr. Joseph R. Calabrese

Question Title

* 1. The session met the stated learning objectives

	1 Learning objective not met	2	3 Learning objective partially met	4	5 Learning objective met
Learning Objective 1: Functional Neuroanatomy and Pathophysiology of Bipolar 1 Disorder	Learning Objective 1: Functional Neuroanatomy and Pathophysiology of Bipolar 1 Disorder 1 Learning objective not met	Learning Objective 1: Functional Neuroanatomy and Pathophysiology of Bipolar 1 Disorder 2	Learning Objective 1: Functional Neuroanatomy and Pathophysiology of Bipolar 1 Disorder 3 Learning objective partially met	Learning Objective 1: Functional Neuroanatomy and Pathophysiology of Bipolar 1 Disorder 4	Learning Objective 1: Functional Neuroanatomy and Pathophysiology of Bipolar 1 Disorder 5 Learning objective met
Learning Objective 2: Impulsivity in Bipolar 1 Disorder, Treatment Delay, and the effect had on Vincent van Gogh	Learning Objective 2: Impulsivity in Bipolar 1 Disorder, Treatment Delay, and the effect had on Vincent van Gogh 1 Learning objective not met	Learning Objective 2: Impulsivity in Bipolar 1 Disorder, Treatment Delay, and the effect had on Vincent van Gogh 2	Learning Objective 2: Impulsivity in Bipolar 1 Disorder, Treatment Delay, and the effect had on Vincent van Gogh 3 Learning objective partially met	Learning Objective 2: Impulsivity in Bipolar 1 Disorder, Treatment Delay, and the effect had on Vincent van Gogh 4	Learning Objective 2: Impulsivity in Bipolar 1 Disorder, Treatment Delay, and the effect had on Vincent van Gogh 5 Learning objective met
Learning Objective 3: Role of Long-Acting Injectable (LAI) Antipsychotics and Identification of Patients Especially Well-suited for Treatment with LAIs	Learning Objective 3: Role of Long-Acting Injectable (LAI) Antipsychotics and Identification of Patients Especially Well-suited for Treatment with LAIs 1 Learning objective not met	Learning Objective 3: Role of Long-Acting Injectable (LAI) Antipsychotics and Identification of Patients Especially Well-suited for Treatment with LAIs 2	Learning Objective 3: Role of Long-Acting Injectable (LAI) Antipsychotics and Identification of Patients Especially Well-suited for Treatment with LAIs 3 Learning objective partially met	Learning Objective 3: Role of Long-Acting Injectable (LAI) Antipsychotics and Identification of Patients Especially Well-suited for Treatment with LAIs 4	Learning Objective 3: Role of Long-Acting Injectable (LAI) Antipsychotics and Identification of Patients Especially Well-suited for Treatment with LAIs 5 Learning objective met

Question Title

* 2. On a scale from 1 (not at all relevant) to 5 (extremely relevant), please rate how relevant this presentation is to you. By relevance, we mean how appropriate the topic and effective the speaker is for you.

1-Not at all relevant

5-Extremely relevant

1-Not at all relevant

5-Extremely relevant

Additional comments:

Question Title

* 3. On a scale from 1 (no opportunity) to 5 (outstanding opportunity for discussion and interaction), please rate how interactive this presentation was for you. By interaction we mean discussion, questions and engagement with the presenter and the topic.

1- No opportunity

5-Outstanding opportunity for discussion and interaction

1- No opportunity

5-Outstanding opportunity for discussion and interaction

Additional Comments:

Question Title

* 1. The session met the stated learning objectives

Question Title

* 2. On a scale from 1 (not at all relevant) to 5 (extremely relevant), please rate how relevant this presentation is to you. By relevance, we mean how appropriate the topic and effective the speaker is for you.

Question Title

* 3. On a scale from 1 (no opportunity) to 5 (outstanding opportunity for discussion and interaction), please rate how interactive this presentation was for you. By interaction we mean discussion, questions and engagement with the presenter and the topic.

Question Title

* 4. Please provide us with any additional comments or observations you would like us to be aware of.